265 related articles for article (PubMed ID: 35070965)
1. Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
Ni J; Guo W; Zhao Q; Cheng X; Xu X; Zhou R; Gu H; Chen C; Chen X
Front Oncol; 2021; 11():746571. PubMed ID: 35070965
[TBL] [Abstract][Full Text] [Related]
2. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
[TBL] [Abstract][Full Text] [Related]
4. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
5. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
[TBL] [Abstract][Full Text] [Related]
6. Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
Xu Q; Li Z
Front Pharmacol; 2021; 12():743073. PubMed ID: 34912215
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
9. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.
Purwar R; Ranjan R; Pal M; Upadhyay SK; Kumar T; Pandey M
World J Surg Oncol; 2023 May; 21(1):157. PubMed ID: 37217940
[TBL] [Abstract][Full Text] [Related]
10. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
11. HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients.
Li L; Gu Y; Zhang M; Shi X; Li Z; Xu X; Sun T; Dong Y; Xue C; Zhu X; Lv R; Jiao K; Ji X; Wang LJ; Zhang Y; Liang Z; Jin Y; Yin R; Wu M; Liang H
NPJ Precis Oncol; 2023 May; 7(1):51. PubMed ID: 37258600
[TBL] [Abstract][Full Text] [Related]
12. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab
Hettle R; McCrea C; Lee CK; Davidson R
Ther Adv Med Oncol; 2021; 13():17588359211049639. PubMed ID: 34616492
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract][Full Text] [Related]
15. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
[TBL] [Abstract][Full Text] [Related]
16. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L
Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.
Huang XZ; Jia H; Xiao Q; Li RZ; Wang XS; Yin HY; Zhou X
Front Oncol; 2020; 10():958. PubMed ID: 32612955
[No Abstract] [Full Text] [Related]
18. Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
Romeo M; Gil-Martín M; Gaba L; Teruel I; Taus Á; Fina C; Masvidal M; Murata P; Fernández-Plana J; Martínez A; Pérez C; García Y; Rodriguez V; Cros S; Parera M; Zanui M; Catot S; Pardo B; Plaja A; Esteve A; Barretina-Ginesta MP
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139574
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Lee EK; Matulonis UA
Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
